Home > Potassium Channel  & > Nateglinide

Nateglinide

A-4166,Starlix,Fastic,Starsis,A4166,A 4166,Senaglinide

Nateglinide是胰岛素促分泌剂，可作用于非胰岛素依赖型糖尿病（NIDDM）。

目录号
EY0298
EY0298
EY0298
EY0298
纯度
99.56%
99.56%
99.56%
99.56%
规格
5 mg
10 mg
50 mg
100 mg
原价
280
485
1300
2600
售价
280
485
1300
2600
库存
现货
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Nateglinide is an insulin secretagog agent that lowers blood glucose levels by stimulating insulin secretion from the pancreas.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] W Hanif and S Kumar. Nateglinide: a new rapid-acting insulinotropic agent. Expert Opinion on Pharmacotherapy, 2(6), 1027-1031 (2001).

    分子式
    C19H27NO3    		 分子量
    317.42    		 CAS号
    105816-04-4    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    62 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    62 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT00858013 Type 2 Diabetes Mellitus Drug: Nateglinide|Drug: Glimepiride Ajou University School of Medicine|Korea University Guro Hospital|Hanyang University|Inha University Hospital|Kyunghee University Medical Center|Myongji Hospital|Bundang CHA Hospital|Yonsei University|Hallym University Medical Center Phase 4 2009-04-01 2011-06-24
    NCT01160029 Healthy Drug: Nateglinide Dr. Reddy's Laboratories Limited Phase 1 2004-10-01 2010-07-12
    NCT01159158 Healthy Drug: Nateglinide Dr. Reddy's Laboratories Limited Phase 1 2007-02-01 2010-07-12
    NCT00928889 Diabetes Mellitus, Type 2 Drug: Nateglinide 120 mg|Drug: Acarbose 50 mg Novartis Pharmaceuticals|Novartis Phase 4 2009-07-01 2012-05-07
    NCT01030952 Diabetes Mellitus, Type 2 Drug: Nateglinide|Drug: Acarbose Novartis Pharmaceuticals|Novartis Phase 4 2009-12-01 2012-09-18
    NCT01316107 Type 2 Diabetes Mellitus Drug: ASP1941|Drug: nateglinide Astellas Pharma Inc Phase 3 2011-02-01 2016-01-19
    NCT00238472 Diabetes Mellitus, Type 2 Drug: nateglinide Novartis Pharmaceuticals|Novartis Phase 4 2003-05-01 2012-04-25
    NCT00319189 Renal Transplant Recipients|Posttransplant Diabetes Mellitus|Posttransplant Impaired Glucose Tolerance Drug: Nateglinide University of Oslo School of Pharmacy Phase 4 2002-11-01 2006-05-09
    NCT00097786 Diabetes Mellitus, Type 2 Drug: Valsartan 160 mg + nateglinide 60 mg|Drug: Valsartan 160 mg + nateglinide placebo|Drug: Nateglinide 60 mg + valsartan placebo|Drug: Valsartan placebo + nateglinide placebo Novartis Pharmaceuticals|Novartis Phase 3 2002-01-01 2011-06-27
    NCT00402909 Type 2 Diabetes Drug: Nateglinide Novartis Pharmaceuticals|Novartis Phase 4 2006-11-01 2017-02-22
    NCT00437918 Diabetes Mellitus|Type 2 Diabetes Mellitus Drug: nateglinide|Drug: acarbose Inje University|Sanofi Phase 4 2007-01-01 2008-03-21
    NCT02088918 Healthy Volunteers Drug: Nateglinide|Drug: Nateglinide/Metformin|Drug: Metformin IlDong Pharmaceutical Co Ltd Phase 1 2012-10-01 2014-03-14
    NCT00189774 Type 2 Diabetes Mellitus|Diabetes Mellitus, Type II Drug: nateglinide Astellas Pharma Inc|Ajinomoto USA, INC. Phase 2|Phase 3 null 2008-03-11
    NCT00461617 Diabetes Drug: Mitiglinide Kissei Pharmaceutical Co., Ltd. Phase 3 2006-08-01 2008-10-20
    NCT00259168 Insulin Resistance|Impaired Fasting Glucose Drug: Nateglinide Bispebjerg Hospital|Novartis|Bayer Phase 4 2003-06-01 2005-11-28
    NCT00369148 Type 2 Diabets Mellitus Drug: nateglinide(drug) mitiglinide(drug) Keio University Phase 4 2004-07-01 2009-08-25
    NCT00212290 Insulin Resistance|Type 2 Diabetes Mellitus Drug: pioglitazone|Drug: nateglinide|Drug: placebo National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 4 2002-11-01 2010-02-12
    NCT02143765 Type 2 Diabetes Mellitus Drug: Mitiglinide|Drug: Acarbose Zhongda Hospital Phase 4 2014-05-01 2016-07-13
    NCT01919489 Type 2 Diabetes Drug: Liraglutide + OADs|Drug: Glargine + OADs Emory University|Novo Nordisk A/S Phase 4 2014-03-01 2016-10-03
    NCT01697592 Type 2 Diabetes Mellitus Drug: Omarigliptin|Drug: Matching placebo to omarigliptin Merck Sharp & Dohme Corp. Phase 3 2012-10-01 2016-10-28

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：